New Delhi: An expert committee at the apex drug regulator, Central Drugs Standards Control Organisation (CDSCO) has deferred its earlier call on Serum Institute of India Pvt Ltd’s vaccine trial. Instead, the panel asked the firm to change its protocol for the phase II and III clinical trials of the vaccine candidate of University of Oxford.
“After detailed deliberation the committee recommended for amendment to the protocol… Accordingly, the firm should submit revised protocol for evaluation of the committee,” the minutes of the subject expert committee (SEC) meeting was quoted by Mint.
The regulatory panel, as part of amendment protocol, has asked the firm to demarcate trials of phase II and III and distribute it across India.
The company has also been asked to specify Indian Council of Medical Research’s (ICMR’s) role in the trial. The Mint report said that an email sent to Serum Institute of India was unanswered.
Keonjhar: Desecration of a Hanuman idol in Barbil area of Odisha's Keonjhar district triggered stiff…
Mumbai: The much-delayed schedule for the 2025 Champions Trophy has been finalised. As per the…
Raipur: Did actor Sunny Leone enroll for a Chhattisgarh government’s beneficiary scheme for economically weaker…
Berhampur: Continuing to target places of worship in different parts of Odisha, burglars struck at…
New York: US President-elect Donald Trump has nominated an Indian American entrepreneur and former aide…
New Delhi: BJP MPs Pratap Sarangi and Mukesh Rajput, who suffered head injuries in the…
This website uses cookies.